«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

21卷

期数:

2015年02期

页码:

126-129

栏目:

临床医学

出版日期:

2015-03-20

文章信息/Info

Title:

Role of plasma lipoprotein-associated phospholipase A2 in the diagnosis of coronary heart disease

文章编号:

1006-8147（2015）02-0126-04

作者:

邵宏培; 徐延敏; 崔占前

(天津医科大学第二医院心脏科,天津300211)

Author(s):

SHAO Hong-pei ; XU Yan-min; CUI Zhan-qian

(Department of Cardiology, The Second Hospital, Tianjin Medical University, Tianjin 300211, China)

关键词:

脂蛋白相关性磷脂酶A2;  冠心病;  高密度脂蛋白胆固醇

Keywords:

lipoprotein-associated ;  phospholipases A2;  coronary heart disease; high density lipoprotein-cholesterol

分类号:

R541.4

DOI:

-

文献标志码:

A

摘要:

目的：探讨血浆脂蛋白相关性磷脂酶A2（Lp-PLA2）水平在冠心病(CHD)患者诊断中的价值。方法：入选怀疑CHD患者104例。对怀疑CHD患者行冠状动脉造影术，依造影结果将患者分为非CHD组(n=52)、CHD组(n=52），其中需要行经皮冠状动脉支架术(PCI)治疗的有25例。检测各组患者血LDL-C、TC、TG、HDL、CRP、 Lp-PLA2水平，记录患者基本临床资料，对各变量与CHD、PCI治疗的关系作Logistic回归分析。结果：Lp-PLA2和CRP水平在CHD组高于非CHD组(P＜0.001）,HDL-C水平在CHD组低于非CHD组(P＜0.05）。回归分析显示Lp-PLA2是CHD和PCI治疗的独立危险因素(P＜0.05),HDL是CHD的保护因素(P＜0.05）。Lp-PLA2的cut-off值为234.5 mmol/L。结论：CHD患者Lp-PLA2水平明显升高，检测血浆Lp-PLA2水平对CHD患者的诊断可能有重要预测价值。

Abstract:

Objective：To investigate the function of plasma lipoprotein-associated phospholipase A2(Lp-PLA2) levels in the diagnosis of coronary heart disease(CHD). Methods：One hundred and four suspected CHD subjects were enrolled. Coronary angiography (CAG) was performed on these patients. According to the result of CAG, patients were divided into CHD group (n=52) and non-CHD group (n=52). Twenty five patients underwent percutaneous coronary intervention（PCI)in the CHD group. The plasma levels of low density lipoprotein-cholesterol (LDL-C),total cholesterol (TC),triglyceride (TG), C reactive protein(CRP),Lp-PLA2,high density lipoprotein-cholesterol (HDL-C)were measured and the basic clinical data were recorded for all groups. Logistic regression was applied to analyze the relationships between each variable and CHD as well as PCI. Results：The plasma level of Lp-PLA2 and CRP were higher in CHD group than that in non-CHD group(P＜0.001).HDL-C levels was lower in CHD group than that in non-CHD group (P＜0.05).Logistic regression analysis revealed that the high plasma level of Lp-PLA2 was the independent risk factor for CHD and PCI treatment(P＜0.05), and high HDL was the protective factor for CHD(P＜0.05).The cut-off value of Lp-PLA2 was 234.5 mmol/L .Conclusion：The plasma levels of Lp-PLA2 is higher in CHD patients, thus can be used to predict plasma Lp-PLA2 levels in CHD patients for their diagnosis.

参考文献/References:

[1]中华医学会心血管病学分会介入心脏病学组中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)[J].中华心血管病杂志,2012,40(4):271
[2]Stafforini D M. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2)[J].Cardiovasc Drugs Ther,2009,23(1):73
[3]Rosenson R S, Vracar-Grabar M, Helenowski I. Lipoprotein associated phospholipase A2 inhibition reduces Generation of oxidized fatty acids: Lp-LPA2 reduces oxidized fatty acids[J].Cardiovasc Drugs Ther,2008,22(1):55
[4]Packard C J, Caslake M J. Lipoprotein associated phospholipase a2 as an Independent predictor of coronary heart disease[J].N Engl J Med,2000,343(16):1148
[5]Kolodgie F D, Burke A P, Skorija K S, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis[J].Arterioscler Thromb Vasc Biol, 2006, 26(11):2523
[6]Sachdeva A, Cannon C P, Deedwania P C, et al.Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines[J].Am Heart J,2009,157(1):111
[7]Larosa J C, Grundy S M, Waters D D, et al.Intensive lipid lowering with atorvastain in patients with stable coronary disease[J].N Engl J Med,2005,352(14):1425
[8]Persson M, Hedblad B, Nelson J J, et al.Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects[J].Arterioscler Thromb Vasc Biol,2007,27(6):1411
[9]Ferguson J F, Hinkle C C, Mehta N N, et al. Trandational studies of lipoproteln associated phospholipaseA2 in inflammation and atherosderosis[J].JAm Coil Cardiol,2012,59(8):764
[10]Dohi T, Miyauehi K, Okazaki S, et al. Decreased circulating lipoprutein-associated phospholipaseA2 levels are associated with coronary plaque regression in patients with acute coronary syndrome[J]. Atherosclerosis, 2011,219(2):907
[11]Patrick W, Serru Y S, Hctor M. Effects of the direct lipoprotein associated PhospholipaseA2 inhibitor darapladib on human coronary atherosclerotic plaque[J].Circulation,2008,118:1172
[12]杨丽,刘寅,刘婷,等.普罗布考联合阿托伐他汀对急性冠脉综合征血脂蛋白相关磷脂酶A2的影响[J].天津医药,2012,40(2):156
[13]李海云,鞠森.Lp-PLA2与冠状动脉斑块的关系及不同剂量的瑞舒伐他汀对其浓度的影响[J].中国医药指南,2013,11(29):437
[14]杨丽,王林,刘寅,等.冠心病脂蛋白相关磷脂酶A2水平与冠脉病变的相关性研究[J].天津医药,2011,39(8):704

相似文献/References:

[1]崔占前,徐延敏.脂蛋白相关性磷脂酶A2及高敏C反应蛋白与左心房内径的关系[J].天津医科大学学报,2015,21(03):196.
　CUI Zhan-qian,XU Yan-min.Relationship between plasma lipoprotein-associated phospholipase A2, high sensitivity C reactive protein and left atrial diameter[J].Journal of Tianjin Medical University,2015,21(02):196.
[2]蒋翠霞,郭亚娜,杜金红,等.冠心病患者GDF-15、Jagged1蛋白表达及意义[J].天津医科大学学报,2019,25(01):77.

备注/Memo

备注/Memo:

作者简介 邵宏培（1983-），男，硕士在读，研究方向：心血管病； E-mail：gcgshp13633143087@126.com.

常用功能

更新日期/Last Update: 2015-03-24